American Journal of Medical Sciences and Medicine
ISSN (Print): 2327-6681 ISSN (Online): 2327-6657 Website: http://www.sciepub.com/journal/ajmsm Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Sciences and Medicine. 2014, 2(2), 41-43
DOI: 10.12691/ajmsm-2-2-3
Open AccessArticle

Coagulation Activities of Patients on Psychotropic Drugs in Nigeria

Afolabi O.I1, Adedire O.A2, Oke O.T2, Omisakin C.T3, and Esan A.J3

1Deparment of Medical Laboratory Services, General Hospital, Oke-Imesi Ekiti, Nigeria

2Department of Haematology and Blood Transfusion, Obafemi Awolowo University Teaching Hospital, Ile – Ife Nigeria

3Department of Haematology and Blood Transfusion, Federal Medical Centre, Ido – Ekiti, Nigeria

Pub. Date: March 30, 2014

Cite this paper:
Afolabi O.I, Adedire O.A, Oke O.T, Omisakin C.T and Esan A.J. Coagulation Activities of Patients on Psychotropic Drugs in Nigeria. American Journal of Medical Sciences and Medicine. 2014; 2(2):41-43. doi: 10.12691/ajmsm-2-2-3

Abstract

The study is being aimed to assess Prothrombin Time and Activated Partial Thromboplastin Time activity in patients on psychotropic drugs. Fifty (50) samples were used, Forty (40) are from the patients on psychotropic drugs while ten (10) are apparently healthy individual that serves as control. The results obtained showed thatPT and APTT of the test subject have a mean value of 26.01 ± 11.04 in compared with the control subject showed a mean value 11.80 ± 1.3. While the result obtained from APTT test subject showed a mean value of 36.70 ± 17.00 compared with the control subject that have a mean value of 36.7.0 ± 3.81. When these results were compared statistically significant difference were observed P<0.01 which indicate a state of prolongation in PT and APTT.

Keywords:
prothrombin psychotropic drugs thromboplastin

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Baker, F.J., Silverton R.E. and Pallister C.J. (2000), Introduction to Medical Laboratory Technology. 7thEdition, Bounty, Page 384-392.
 
[2]  Boyd and Alan, (1995), British Medical Journal Psychiatry, Bromocriptie and Psychosis (66) Page 89-95.
 
[3]  Conoso R.T., Hulton R.A. and Deylcin D.A (1977), Chloropromazine Induced Inhibitor of Blood Coagulation American Journal, Haematology 2: 183-191
 
[4]  Dilsaver, S.C. and Alessi, N.T (2000), AntiPsychotic Withdrawal Symptoms, Phenomenology and Pathophysiology. Acts PsychiatryScand, 77(3) Page 241-246.
 
[5]  Emdex, (2010), The Complete Drug Formulary, Healthy Professionals, Lph, 2010/11 Editions, Page 13-31.
 
[6]  Furie, B.C. (2005), Thrombus Formulation Invivo. Journal at Clinical Investigation. 115(12): 355-3365.
 
[7]  Gelder and Michael (2005), “Psychiatry”. Oxford University Press Inc. New York. ISBN.
 
[8]  Haggs .S., Spigset .O. and T. G. Soerstrom T.G. (2000), Associated between Venous Thromboembolism and Clozapine. A study of the WHO Database of Adverse Drugs Reaction (355); Page 1115-1156.
 
[9]  Harper and Douglas (2001), “Hallucinate”. Online Etymology Dictionary www. Etvrnoline.com
 
[10]  Hoffbrand, A.V., Pettit J.E and Moses P.A.N (2004), Essential Haematology, 4th Edition, Blackwell, Page 236-273.
 
[11]  Hougie .C. and Cecil .B. (1963), Fundamental of Blood Coagulation in Clinical Medicine, McGraw-Hill, New York 1963.
 
[12]  International Committee for the Nomenclature of Blood Clotting factors (1962), Nomenclature of Blood Clotting factor. British Medical Journal (465) page 17-20.
 
[13]  Leweke F.M., Koethe D. Pahliseh F., Schrieber, D., Gerth C.W., Nolden B.M., Klosterkotter J., and Helimich (2009), Antipsychotic effect of Cnnabidol, European Psychiatry 24 (207) Page 70440-70447.
 
[14]  Macfalene R.G. (1964), An EmzymeCasada In Blood clotting Mechanism and its function as Biological Amplifer nature 202: 498-499.
 
[15]  McKeith; Lan G. (2002), “Dementia with lewyBodie” British Journal of Psychiatry (180) Page 144-147.
 
[16]  Mohammed H.Z. Stanley Zucker, Frederick M., Gails S.R., James A.H., and Andre O.V. (2005), Coagulation Disorder in Chloromazie Treated Patient, Northorpot, New York page 15-16 (Pubmed).
 
[17]  Morawitz P. (1905), “Die ChemiederBlutgerinnung” Ergehn Physiology (4) Page 307-422
 
[18]  Murpy: B.P, Chung Y.C., Park T.W. and McGorry P.D. (2006), Pharmacological Treatment of Primary Negative Symptoms in Schizophrenia, “A Systematic Review”, Schiozopherma Research 88 (1-3), Page 5-25.
 
[19]  Mustapha, R.O (2001), The Easir Approach to Pharmacology for all Health Professionals; ISBN, Page 167-182.
 
[20]  Nelson J., Juhan – Vague .I. and Thompson S.G (), Involvement of theHaemostaic system in the Insulin Resistance Syndrome. Arterioscler Thrombin (13) 1865-73.
 
[21]  Ochei, J. and Kolhatkar A., (2008), Medical Laboratory Science, Theory and Practices, Tata McGraw-Hill, Page 311-347.
 
[22]  Osinbowale O. Ali .H., Chi Y.W. (2010), Venous Thromboembolism; A Clinical Review. Postgraduate Medical (122) Page 54-65 (Pubmed).
 
[23]  Owen, R. and Charles, A. (2001), History of Blood Coagulation, May foundation for medical Education and Research, Rochester, Minnesota.
 
[24]  Perkins, D. O. (2002), Predictors of Noncompliance in Patients with Sehizophrenia. Journal Clinic Psychiatry 63(12) Page 1121-1128 (Pubmed).
 
[25]  Sander, J.W Hart Y.M., Trimble M.R. andShorvon S.D. (1991), Vigabatrin and Psychosis. Journal of Neurology, Neurosurgery and Psychiatric54(5) Pages 435-4391.
 
[26]  Wang, P. S. (2010), Rethinking Mental Illness, The British Journal of Psychiatry. 303 (19) Page 1970-1971.
 
[27]  Zornbery, G.L. and Jick, H. (2000), Antipsychotic Drugs used and the Risk of First-time Idiopathic Venous Thromboembolism, A Case Control Study, Lancet, (356), Page 1219-1223 (Pubmed).